Welcome to DailyUpdates Immunology & Inflammatory Diseases - the R&D community's bulletin of breaking research, clinical trials and drug development news. This page will update each day. You have access for 1 more day(s). To receive DailyUpdates by e-mail register here

PubMed DailyUpdates: Breaking Scientific Publications for the Drug Discovery Community

DailyUpdates by e-mail - the publication tracker for the drug discovery community

Immunology & Inflammatory Diseases

If this icon appears after any of our listed articles, the author is able to provide reprints. Articles denoted by an Licensing Op. icon describe data relevant to licensing opportunities. The report icon, , links through to full analyses relating to pharmaceutical/market developments relating to this work


Today's journal articles

Crystal structures of human RIP2 kinase catalytic domain complexed with ATP - competitive inhibitors: Foundations for understanding inhibitor selectivity.

Therapeutic Potential of Hyporesponsive CD4(+) T Cells in Autoimmunity.

Do you need further information on any of the agents being evaluated in the trial(s) below?  Let us know...

New Clinical Trials

No clinical trials today

Previous Journal Entries

No previous journal articles today

Today's News Items

Sun Pharma and Almirall enter into a License Agreement for Tildrakizumab in Europe for Psoriasis

Caladrius Biosciences Receives FDA Fast Track Designation for CLBS03 to Treat Recent Onset Type 1 Diabetes

NICE draft guidance recommends new drug for people with ankylosing spondylitis

Apotex Launches First Generic Version of Merck's Nasonex

GSK in-licenses anti-IL-33R monoclonal antibody for severe asthma from Janssen

RedHill Announces Last Patient Visit in Phase IIa Study with RHB-104 for Multiple Sclerosis

Training Courses & Meetings

No events listed

Previous News Items

Sunovion Announces Results of Phase 3 Long-Term Safety Study Showing SUN-101/eFlow® (glycopyrrolate) Was Well-Tolerated in People with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease (COPD)

CHMP Issues Positive Opinion for ORENCIA® (abatacept) in the Treatment of Highly Active and Progressive Disease in Adult Patients with Rheumatoid Arthritis not Previously Treated with Methotrexate in the EU

AbbVie and Bristol-Myers Squibb Announce Oncology Clinical Collaboration to Evaluate the Combination of Rova-T plus Opdivo and Opdivo + Yervoy Regimen

Almirall announces a global licensing agreement with Patagonia for congenital ichthyosis

Tobira Therapeutics Announces Clinically and Statistically Significant Improvement in Liver Fibrosis From Phase 2b CENTAUR NASH Trial at One Year

Sun Pharma and Almirall enter into a License Agreement for Tildrakizumab in Europe for Psoriasis

Omeros Corporation Confirms OMS721 Phase 3 Development Plan with European Medicines Agency

Pfizer Announces Positive Top-Line Results from Pivotal Phase 3 Maintenance Trial of Oral XELJANZ® (Tofacitinib Citrate) in Ulcerative Colitis